Terumo Cardiovascular Group competitors

Results-focused senior executive whose strategic vision, leadership and commitment to success consistently led to dynamic gains in revenue, profit, operational performance and competitive advantage in US and global markets. Leverages instinctive ability to zero in on product and market potential to achieve objectives in start-up, turnaround and growth environments.Selected Achievements:Led $400 million division to record growth in worldwide sales and profit, with 14% year-over-year revenue gains and 10 point improvement in the bottom line.Key member of executive team that negotiated the $2.2 billion acquisition of Gyrus ACMI by Olympus Corporation.Built US division to $96.6 million in sales with average annual revenue growth of 35% for 3 consecutive years.Strategic forward thinker - initiated and spearheaded a comprehensive $700 million business restructuring to comply with changing healthcare laws and regulations while concurrently streamlining process, driving productivity and increasing customer satisfaction. The initiative resulted in a 15% reduction in expenses and a 5% revenue increase.

Michael A. Mussallem, age 56, has been chairman and CEO of Edwards Lifesciences, Inc. since 2000. Prior to 2000, Mussallem held a variety of positions with increasing responsibility in engineering, product development and senior management at Baxter International Inc., including Group Vice President of its CardioVascular business from 1994 to 2000 and Group Vice President of the Biopharmaceutical business from 1998 to 2000. From 1996 until 1998, he was the Chairman of Baxter's Asia Board overseeing Baxter's operations throughout Asia. Mr. Mussallem is chairman of the board of directors of the Advanced Medical Technology Association (AdvaMed), and serves as a member of the board for Advanced Medical Optics. He is also on the boards and executive committees of the California Healthcare Institute and OCTANe, and is a trustee of the University of California, Irvine Foundation. He received a bachelor's degree in chemical engineering in 1974 and an honorary doctorate in 1999 from the Rose-Hulman Institute of Technology in Indiana.

Bill Valle is Executive Vice President of Fresenius Medical Care North America (FMCNA) and President of Fresenius Medical Services (FMS), the largest division of FMCNA. He is responsible for the successful management of more than 2,150 outpatient facilities, 1,400 inpatient programs, and 800 home dialysis programs across the U.S. Approximately 165,000 dialysis patients receive life-sustaining dialysis therapy in these facilities. Bill previously served as President of Fresenius Medical Care Integrated Renal Services. In that capacity, he led several of the organization’s vital business functions, integrating them into a high performance renal network that can improve the outcomes and reduce the costs of managing renal disease. These include Fresenius Vascular Care, FreseniusRx, Spectra Laboratories, FMS Business Development, FMS Inpatient Services and FMS Real Estate and Construction Services. Prior to joining FMCNA, Bill had 22 years of experience in the dialysis industry, serving in executive roles in sales, marketing and business development, as well as ownership in several private dialysis centers.

Dynamic, results-oriented leader with a strong track record of performance in turnaround and high-paced organizations. Utilize keen analysis and insights and team approach to drive organizational improvements and implementation of best practices. Superior interpersonal skills, capable of resolving multiple and complex (sales, human resources, legal, financial, operational) issues and motivating staff to peak performance. Excellent political connections developed as selected member of Fiorello LaGuardia's mayoral team.

Gary Burbach is a Chief Executive Officer at Thoratec and is based in Pleasanton, California.